Company Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:35:06 2025-01-21 am EST			5-day change	1st Jan Change
565.50 ^DKK	+2.58%		-5.22%	-10.06%

Jan. 03	New Year, Soft Start
Jan. 03	BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform	MT

Business description: Novo Nordisk A/S

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- diabetes and obesity treatment products (92.6%);

- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Number of employees: 71,880

Sales by Activity: Novo Nordisk A/S

Fiscal Period: December	2019	2020	2021	2022	2023
Diabetes and Obesity Care	103B	108B	122B	156B	215B
Rare Disease	19.18B	18.93B	19.2B	20.54B	17.16B

See all business segments

Geographical breakdown of sales: Novo Nordisk A/S

Fiscal Period: December	2019	2020	2021	2022	2023
United States of America (USA)	57.49B	57.82B	63.01B	84.66B	128B
EMEA	-	34.3B	37.71B	44.24B	50.87B
Rest of the World	-	17.45B	19.81B	25.4B	28.08B
Region China	12.84B	14.08B	16.02B	16.21B	16.69B
North America (Excl. US)	2.97B	3.29B	4.25B	6.45B	9.1B
Africa, Asia, Middle East and Oceania (AAMEO)	14.09B	-	-	-	-
Latin America	4.92B	-	-	-	-
Japan & Korea	6.45B	-	-	-	-
Europe	23.26B	-	-	-	-

See all geographic segments

Managers: Novo Nordisk A/S

Director	Title	Age	Since
Lars Fruergaard Jorgensen CEO	Chief Executive Officer	59	2016-12-31
Karsten Munk Knudsen DFI	Director of Finance/CFO	54	2018-02-14
Henrik Ehlers Wulff CTO	Chief Tech/Sci/R&D Officer	55	2018-12-31
Marcus Schindler CTO	Chief Tech/Sci/R&D Officer	58	2021-02-28
Stephen Gough CTO	Chief Tech/Sci/R&D Officer	-	2015-09-30

See NOVO NORDISK A/S governance

Members of the board: Novo Nordisk A/S

Manager	Title	Age	Since
Sylvie Grégoire BRD	Director/Board Member	63	2015-03-18
Kasim Kutay BRD	Director/Board Member	60	2017-03-22
Helge Lund CHM	Chairman	62	2018-03-21
Mette Bøjer Jensen BRD	Director/Board Member	50	2018-03-21
Thomas Rantzau BRD	Director/Board Member	53	2018-03-21
Andreas Fibig BRD	Director/Board Member	62	2018-02-28
Martin MacKay BRD	Director/Board Member	69	2018-02-28
Laurence Debroux BRD	Director/Board Member	55	2019-03-20
Henrik Poulsen BRD	Director/Board Member	58	2021-03-24
Elisabeth Christensen BRD	Director/Board Member	60	2022-03-23

Composition of the Board of Directors

Shareholders: Novo Nordisk A/S

Name	Equities	%	Valuation
Novo Holdings A/S (Investment Company) 5.610 %	190,183,000	5.610 %	16 522 M kr
NOVO NORDISK A/S 0.6641 %	22,514,974	0.6641 %	1 956 M kr
State Street Global Advisors Ltd. 0.2092 %	7,092,227	0.2092 %	616 M kr
MFS International Singapore Pte Ltd. 0.1420 %	4,814,384	0.1420 %	418 M kr
Sjunde AP-fonden 0.1370 %	4,643,506	0.1370 %	403 M kr

Name	Equities	%	Valuation
Caixa DTVM SA 0.001349 %	365,960	0.001349 %	4 M kr
Warren Brasil Gestão e Administração e Recursos Ltda. 0.000050 %	13,600	0.000050 %	147 437 kr
XP Allocation Asset Management Ltda. 0.000039 %	10,690	0.000039 %	115 890 kr
BNY Mellon Serviços Financeiros DTVM SA 0.000006 %	1,733	0.000006 %	18 787 kr
BRAM - Bradesco Asset Management SA DTVM 0.000000 %	17	0.000000 %	184 kr

Name	Equities	%	Valuation
Novo Holdings A/S (Investment Company) 100.00 %	1,074,872,000	100.00 %	93 381 M kr
ANIMA Sgr SpA 0.0262 %	281,375	0.0262 %	24 M kr
Prevaal Finance SAS 0.008515 %	91,525	0.008515 %	8 M kr
OLZ AG 0.001913 %	20,557	0.001913 %	2 M kr

Name	Equities	%	Valuation
Jennison Associates LLC 0.5957 %	20,195,957	0.5957 %	1 737 M kr
Fidelity Management & Research Co. LLC 0.5289 %	17,931,577	0.5289 %	1 542 M kr
Eaton Vance Management 0.4237 %	14,365,402	0.4237 %	1 236 M kr
Merrill Lynch International 0.4226 %	14,326,429	0.4226 %	1 232 M kr
Fisher Asset Management LLC 0.3925 %	13,305,474	0.3925 %	1 145 M kr

List of NOVO NORDISK A/S shareholders

Holdings: Novo Nordisk A/S

Name	Equities	%	Valuation
NOVO NORDISK A/S 0.70%	23,691,366	0.70%	2,058,212,060 $
NNIT A/S 17.50%	4,375,000	17.50%	56,324,319 $
INNATE PHARMA 11.86%	9,817,546	11.86%	19,640,884 $

Company details: Novo Nordisk A/S

Novo Nordisk A/S

Novo Allé 1

2880, Bagsværd

+45 44 44 88 88

http://www.novonordisk.com

Group companies: Novo Nordisk A/S

Name	Category and Sector
Novo Nordisk India Pvt Ltd. Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases.	Medical/Nursing Services
Velfærdsfonden for Novo Nordisk A/S	Investment Trusts/Mutual Funds
NNE A/S NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark.	Engineering & Construction
World Diabetes Foundation	Investment Trusts/Mutual Funds
Novo Nordisk Health Care AG Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland.	Pharmaceuticals: Major

See all subsidiaries

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
NOVO NORDISK A/S	+1.62%	-5.91%	-23.30%	+76.56%	341B
ELI LILLY AND COMPANY	-4.21%	-9.00%	+15.45%	+198.49%	653B
JOHNSON & JOHNSON	-0.50%	+1.77%	-9.06%	-11.03%	354B
ABBVIE INC.	-1.23%	-2.93%	+4.12%	+28.96%	303B
MERCK & CO., INC.	-2.76%	-3.03%	-17.64%	+21.26%	248B
ROCHE HOLDING AG	-0.52%	+1.06%	+7.43%	-26.19%	236B
ASTRAZENECA PLC	+0.57%	+2.05%	+2.44%	+23.95%	206B
NOVARTIS AG	+0.18%	-0.59%	-5.11%	+12.16%	197B
PFIZER, INC.	-0.72%	-1.87%	-7.00%	-51.34%	149B
AMGEN INC.	+0.99%	+0.71%	-11.60%	+18.88%	146B
Average	-0.66%	-1.83%	-4.43%	+29.17%	283.38B
Weighted average by Cap.	-1.19%	-3.21%	-2.00%	+57.24%